Toronto, Ontario and Tel Aviv, Israel–(Newsfile Corp. – May 12, 2023) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Research, LLC (“Litchfield”) to perform investor relations services and activities, as defined in accordance with the policies of the TSX Venture Exchange (“TSXV”) and applicable securities laws.
Pursuant to the agreement with Litchfield, the Company will pay an annual cash fee of USD$14,000, of which USD$5,000 is payable upon entering into the agreement, with the remaining amount payable in three equal installments over the following nine months. Certain investor relations services may also be billed on an ad hoc basis. The term of the agreement is for one year, subject to termination by NurExone at any time without penalty. Litchfield does not own or control any securities of the Company. Litchfield operates out of Lakeville, Connecticut and is engaged to publish equity research on the Company on 15 global financial platforms and target its research to institutional investors who are invested in similar companies.